Actuate Therapeutics is currently advancing a novel best-in-class GSK-3β inhibitor into the clinic for oncology and fibrotic diseases Across multiple institutions, researchers have conducted studies of 9-ING-41 with compelling results. The IND was approved in 1Q18 and a groundbreaking Phase 1/2 study is ready to initiate in 2018.
